Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name INCAGN02385 + INCAGN02390 + Retifanlimab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
INCAGN02385 INCAGN 02385|INCAGN-02385|tuparstobart LAG3 Antibody 19 INCAGN02385 is a antibody that targets LAG-3, potentially resulting in increased T-cell response (AACR Annual Meeting 2018, Abstract 3919).
INCAGN02390 INCAGN 02390|INCAGN-02390 TIM-3 Antibody 9 INCAGN02390 is an antibody that targets the immune inhibitory receptor TIM-3, potentially resulting in decreased tumor growth when combined with other immune checkpoint inhibitors (Cancer Res July 1 2018 (78) (13 Supplement) 3825).
Retifanlimab Zynyz MGA 012|INCMGA00012|MGA012|retifanlimab-dlwr Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 130 Zynyz (retifanlimab) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). Zynyz (retifanlimab) is FDA approved for use in adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma, and in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) or as a single agent for patients with anal canal squamous cell carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06056895 Phase II INCAGN02385 + INCAGN02390 + Retifanlimab Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC) Active, not recruiting USA 0
NCT04370704 Phase Ib/II INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies Active, not recruiting USA | AUS 0
NCT06290622 Phase I INCAGN02385 + INCAGN02390 + Retifanlimab PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Withdrawn 0
NCT05287113 Phase II INCAGN02385 + Retifanlimab Retifanlimab INCAGN02385 + INCAGN02390 + Retifanlimab Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS >= 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting USA | POL | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BEL 4


Additional content available in Icon for CKB-BoostCKB BOOST